Amrad, Ludwig beef up agreement

Amrad (ASX:AML) and the Ludwig Institute for Cancer Research have strengthened their collaboration for the development of vascular endothelial growth factor B (VEGF-B), which has potential applications in cancer and cardiovascular disease.

Under the agreement, the partners will coordinate research, development and commercialisation activities to appropriately leverage the combined expertise of the two groups. Intellectual property generated since the original agreement was reached will also be brought together.

Amrad is developing antibodies against VEGF-B for evaluation as potential cancer treatments, in addition to evaluating VEGF-B in coronary disease models. Ludwig researchers in Sweden and Finland will work closely with Amrad to move therapies based on VEGF-B into the clinic as soon as possible.